<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="26d08996-47e6-4f3c-91f9-a13a6aa936af"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LETAIRIS<sup>Â®</sup> safely and effectively. See full prescribing information for LETAIRIS.
      <br/>
      <br/>
Letairis (ambrisentan) tablets, for oral use
 <br/>
Initial U.S. Approval: 2007
</title>
   <effectiveTime value="20250404"/>
   <setId root="725d4e73-6c83-477a-adc6-0ae4a133a844"/>
   <versionNumber value="26"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="185049848"/>
            <name>Gilead Sciences, Inc</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="402a2472-5f81-41f0-9d72-b0df0fe54af0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250404"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-0801" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Letairis</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>AMBRISENTAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LMI26O6933" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALUMINUM OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SOYBEAN LECITHIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="HW6NV07QEC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMBRISENTAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HW6NV07QEC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMBRISENTAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-0801-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20070615"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-0801-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20070615"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-0801-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070615"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-0801-5" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070615"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-0801-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20070615"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-0801-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070615"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022081" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070615"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48350" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SQUARE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GSI;5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-0802" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Letairis</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>AMBRISENTAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="HW6NV07QEC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMBRISENTAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HW6NV07QEC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMBRISENTAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LMI26O6933" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALUMINUM OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SOYBEAN LECITHIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-0802-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20070615"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61958-0802-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20070615"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-0802-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070615"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-0802-5" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070615"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022081" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070615"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="red" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GSI;10</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="eca1eb0c-efe0-43cd-8d8b-83ef6f4f00d5"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: EMBRYO-FETAL TOXICITY</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Letairis is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Therefore, for females of reproductive potential, exclude pregnancy before the initiation of treatment with Letairis. Advise use of effective contraception before initiation, during treatment, and for one month after treatment with Letairis <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2) </linkHtml>
                           <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content> When pregnancy is detected, discontinue Letairis as soon as possible (<linkHtml href="#S5.1">5.1</linkHtml>).</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: EMBRYO-FETAL TOXICITY</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Based on animal data Letairis may cause fetal harm if used during pregnancy (<linkHtml href="#S4.1">4.1</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">Females of reproductive potential: Exclude pregnancy before the start of treatment. Use effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with Letairis (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S4.1">4.1</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">When pregnancy is detected, discontinue Letairis as soon as possible (<linkHtml href="#S5.1">5.1</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="5ce6b650-55d2-4e42-b165-c81edcdb9d2c"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="75%" align="left" valign="top"/>
                           <col width="25%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <list listType="unordered">
                                       <item>
                                          <linkHtml href="#BOX">Box Warning</linkHtml>
                                       </item>
                                       <item>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</item>
                                       <item>Dosage and Administration, Pregnancy Testing in <br/>Â Â Â Females of Reproductive Potential (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                                       <item>Warnings and Precautions for Use <br/>Â Â Â Embryo-fetal Toxicity (<linkHtml href="#S5.1">5.1</linkHtml>) 
                        <br/>Â Â Â Ambrisentan Risk Evaluation and Mitigation Strategy (REMS) (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                                    </list>
                                 </td>
                                 <td>04/2025<br/>04/2025<br/>
                                    <br/>04/2025<br/>
                                    <br/>04/2025<br/>
                                    <br/>
                                    <content styleCode="italics">(removed) </content>04/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="00eaeaa9-ce63-433e-bb17-c9d07b5d59e7"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">Letairis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>To improve exercise ability and delay clinical worsening. </item>
                     <item>In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>Studies establishing effectiveness included predominantly patients with WHO Functional Class IIâIII symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients:</paragraph>
                        <list listType="unordered">
                           <item>To improve exercise ability and delay clinical worsening.</item>
                           <item>In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. </item>
                        </list>
                        <paragraph>Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class IIâIII symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) (<linkHtml href="#S1">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="f5308455-cdd3-42d5-b533-8a4086c98dee"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Initiate treatment at 5 mg once daily (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                           <item> May be started with tadalafil (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                           <item> Titrate at 4-week intervals as needed and tolerated (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                           <item> Do not split, crush, or chew tablets (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="011a50eb-7a5b-4ace-881b-14c07ba67257"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adult Dosage</title>
                     <text>
                        <paragraph>Initiate treatment at 5 mg once daily, with or without tadalafil 20 mg once daily. At 4-week intervals, either the dose of Letairis or tadalafil can be increased, as needed and tolerated, to Letairis 10 mg or tadalafil 40 mg.</paragraph>
                        <paragraph>Do not split, crush, or chew tablets. </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="c58119f1-bcf7-4680-afea-c52061202a76"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.2 Pregnancy Testing in Females of Reproductive Potential</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Exclude pregnancy before initiating treatment with Letairis in females of reproductive potential <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="0ceb6336-4444-4b2d-a8f9-8af6395d00e3"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>5 mg and 10 mg film<content styleCode="bold">-</content>coated tablets for oral administration</paragraph>
                  <list listType="unordered">
                     <item>Each 5 mg tablet is square convex, pale pink, with â5â on one side and âGSIâ on the other side.</item>
                     <item>Each 10 mg tablet is oval convex, deep pink, with â10â on one side and âGSIâ on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablet: 5 mg and 10 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="185819cb-64a5-4fc5-bc70-d86762de43af"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Pregnancy (<linkHtml href="#S4.1">4.1</linkHtml>)</item>
                           <item> Idiopathic Pulmonary Fibrosis (<linkHtml href="#S4.2">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="6d7568ec-fe28-42c8-b564-4e186ef669e2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Pregnancy</title>
                     <text>
                        <paragraph>Letairis may cause fetal harm when administered to a pregnant female. Letairis is contraindicated in females who are pregnant. Letairis was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.2">
                     <id root="008c8051-3a17-412e-8de9-0691c81819a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Idiopathic Pulmonary Fibrosis</title>
                     <text>
                        <paragraph>Letairis is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF), including IPF patients with pulmonary hypertension (WHO Group 3) 
         
 
  <content styleCode="italics">[see 
          
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>].
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="3868d08f-8a25-48f7-b053-a88e3ec58840"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Fluid retention may require intervention (<linkHtml href="#S5.2">5.2</linkHtml>).</item>
                           <item> If patients develop acute pulmonary edema during initiation of therapy with Letairis, consider underlying pulmonary veno-occlusive disease and discontinue treatment if necessary (<linkHtml href="#S5.3">5.3</linkHtml>).</item>
                           <item> Decreases in sperm count have been observed in patients taking endothelin receptor antagonists (<linkHtml href="#S5.4">5.4</linkHtml>).</item>
                           <item> Decreases in hemoglobin have been observed within the first few weeks; measure hemoglobin at initiation, at 1 month, and periodically thereafter (<linkHtml href="#S5.5">5.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="0921c308-50c4-4a2a-a2c5-550dd6802c7c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.1 Embryo-fetal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Based on data from animal reproduction studies, Letairis may cause fetal harm when administered during pregnancy and is contraindicated during pregnancy. The available human data for endothelin receptor antagonists do not establish the presence or absence of major birth defects related to the use of Letairis. Advise patients who can become pregnant of the potential risk to a fetus. Obtain a pregnancy test prior to initiation of treatment with Letairis. Advise patients who can become pregnant to use effective contraception prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with Letairis. When pregnancy is detected, discontinue use as soon as possible <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, and <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="95644c5e-d3fa-4216-b6a5-835c7f9010a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Fluid Retention</title>
                     <text>
                        <paragraph>Peripheral edema is a known class effect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH. In the placebo-controlled studies, there was an increased incidence of peripheral edema in patients treated with doses of 5 or 10 mg Letairis compared to placebo 
         
 
  <content styleCode="italics">[see 
          
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Most edema was mild to moderate in severity.
        

</paragraph>
                        <paragraph>In addition, there have been postmarketing reports of fluid retention in patients with pulmonary hypertension, occurring within weeks after starting Letairis. Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure.</paragraph>
                        <paragraph>If clinically significant fluid retention develops, with or without associated weight gain, further evaluation should be undertaken to determine the cause, such as Letairis or underlying heart failure, and the possible need for specific treatment or discontinuation of Letairis therapy.</paragraph>
                        <paragraph>Peripheral edema/fluid retention is more common with Letairis plus tadalafil than with Letairis or tadalafil alone.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="6869579a-e382-4651-a15e-58ddd9bc27b0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Pulmonary Edema with Pulmonary Veno-occlusive Disease (PVOD)</title>
                     <text>
                        <paragraph>If patients develop acute pulmonary edema during initiation of therapy with vasodilating agents such as Letairis, the possibility of PVOD should be considered, and if confirmed Letairis should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="f6db0201-5798-44a8-9b61-42460550fba7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Decreased Sperm Counts</title>
                     <text>
                        <paragraph>Decreased sperm counts have been observed in human and animal studies with another endothelin receptor antagonist and in animal fertility studies with ambrisentan. Letairis may have an adverse effect on spermatogenesis. Counsel patients about potential effects on fertility 
         
 
  <content styleCode="italics">[see 
          
  
   <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml> and 
          
  
   <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="6dd1792a-0f51-4047-8a8c-593d0cca3d61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hematological Changes</title>
                     <text>
                        <paragraph>Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Letairis. These decreases were observed within the first few weeks of treatment with Letairis, and stabilized thereafter. The mean decrease in hemoglobin from baseline to end of treatment for those patients receiving Letairis in the 12-week placebo-controlled studies was 0.8 g/dL.</paragraph>
                        <paragraph>Marked decreases in hemoglobin (&gt;15% decrease from baseline resulting in a value below the lower limit of normal) were observed in 7% of all patients receiving Letairis (and 10% of patients receiving 10 mg) compared to 4% of patients receiving placebo. The cause of the decrease in hemoglobin is unknown, but it does not appear to result from hemorrhage or hemolysis.</paragraph>
                        <paragraph>In the long-term open-label extension of the two pivotal clinical studies, mean decreases from baseline (ranging from 0.9 to 1.2 g/dL) in hemoglobin concentrations persisted for up to 4 years of treatment.</paragraph>
                        <paragraph>There have been postmarketing reports of decreases in hemoglobin concentration and hematocrit that have resulted in anemia requiring transfusion.</paragraph>
                        <paragraph>Measure hemoglobin prior to initiation of Letairis, at one month, and periodically thereafter. Initiation of Letairis therapy is not recommended for patients with clinically significant anemia. If a clinically significant decrease in hemoglobin is observed and other causes have been excluded, consider discontinuing Letairis.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="0551f1e9-860a-4452-b18d-983fb725dd14"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Clinically significant adverse reactions that appear in other sections of the labeling include:</paragraph>
                  <list listType="unordered">
                     <item>Embryo-fetal Toxicity 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, 
         
   
    <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
        
  
   </content>
                     </item>
                     <item>Fluid Retention 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
        
  
   </content>
                     </item>
                     <item>Pulmonary Edema with PVOD 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
        
  
   </content>
                     </item>
                     <item>Decreased Sperm Count 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
        
  
   </content>
                     </item>
                     <item>Hematologic Changes 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
        
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Most common adverse reactions (&gt;3% compared to placebo) are peripheral edema, nasal congestion, sinusitis, and flushing (<linkHtml href="#S6.1">6.1</linkHtml>).</item>
                           <item> When used in combination with tadalafil, most common adverse reactions (&gt;5% compared with either monotherapy) are peripheral edema, headache, nasal congestion, cough, anemia, dyspepsia, and bronchitis (<linkHtml href="#S6.1">6.1</linkHtml>).</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at (1-800-445-3235, Option 3) or FDA at 1-800-FDA-1088 or <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="2f1d7a64-c7e2-4a12-8ab4-0a8012ea85ca"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Safety data for Letairis are presented from two 12-week, placebo-controlled studies (ARIES-1 and ARIES-2) in patients with pulmonary arterial hypertension (PAH), and one randomized, double-blind, active-controlled trial in 605 patients with PAH (AMBITION) comparing Letairis plus tadalafil to Letairis or tadalafil alone. The exposure to Letairis in these studies ranged from 1 day to 4 years (N=357 for at least 6 months and N=279 for at least 1 year).</paragraph>
                        <paragraph>In ARIES-1 and ARIES-2, a total of 261 patients received Letairis at doses of 2.5, 5, or 10 mg once daily and 132 patients received placebo. The adverse reactions that occurred in &gt;3% more patients receiving Letairis than receiving placebo are shown in Table 1.</paragraph>
                        <table width="75%">
                           <caption>Table 1           Adverse Reactions with Placebo-Adjusted Rates &gt;3% in ARIES-1 and ARIES-2</caption>
                           <col width="25%" align="left" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Placebo<br/>(N=132)</th>
                                 <th colspan="2" styleCode="Rrule">Letairis <br/>(N=261)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">n (%)</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">n (%)</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Placebo-adjusted (%)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Peripheral edema</td>
                                 <td styleCode="Rrule">14 (11)</td>
                                 <td styleCode="Rrule">45 (17)</td>
                                 <td styleCode="Rrule">6</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nasal congestion</td>
                                 <td styleCode="Rrule">2 (2)</td>
                                 <td styleCode="Rrule">15 (6)</td>
                                 <td styleCode="Rrule">4</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Sinusitis</td>
                                 <td styleCode="Rrule">0 (0)</td>
                                 <td styleCode="Rrule">8 (3)</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Flushing</td>
                                 <td styleCode="Rrule">1 (1)</td>
                                 <td styleCode="Rrule">10 (4)</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Most adverse drug reactions were mild to moderate and only nasal congestion was dose-dependent. </paragraph>
                        <paragraph>Few notable differences in the incidence of adverse reactions were observed for patients by age or sex. Peripheral edema was similar in younger patients (&lt;65 years) receiving Letairis (14%; 29/205) or placebo (13%; 13/104), and was greater in elderly patients (â¥65 years) receiving Letairis (29%; 16/56) compared to placebo (4%; 1/28). The results of such subgroup analyses must be interpreted cautiously.</paragraph>
                        <paragraph>The incidence of treatment discontinuations due to adverse events other than those related to PAH during the clinical trials in patients with PAH was similar for Letairis (2%; 5/261 patients) and placebo (2%; 3/132 patients). The incidence of patients with serious adverse events other than those related to PAH during the clinical trials in patients with PAH was similar for placebo (7%; 9/132 patients) and for Letairis (5%; 13/261 patients).</paragraph>
                        <paragraph>During 12-week controlled clinical trials, the incidence of aminotransferase elevations &gt;3 Ã upper limit of normal (ULN) were 0% on Letairis and 2.3% on placebo. In practice, cases of hepatic injury should be carefully evaluated for cause.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="8dbe5104-c811-4aba-b8c5-e047229ebcd2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="underline">Combination Use with Tadalafil</content>
                                 </content>
                              </paragraph>
                              <paragraph>The mean exposure to Letairis + tadalafil in the AMBITION study was 78.7 weeks. The adverse reactions that occurred in &gt;5% more patients receiving Letairis + tadalafil than receiving Letairis or tadalafil monotherapy in AMBITION are shown in Table 2. </paragraph>
                              <table width="75%" ID="Table2">
                                 <caption>Table 2    Adverse Reactions Reported More Commonly (&gt;5%) on Letairis + Tadalafil than on Letairis or Tadalafil Monotherapy (ITT) in AMBITION </caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="bottom">Adverse Reactions</th>
                                       <th styleCode="Rrule">Letairis  + Tadalafil<br/> Combination  Therapy<br/> (N=302)<br/>n  (%)</th>
                                       <th styleCode="Rrule">Letairis <br/>Monotherapy <br/>(N=152) <br/>n  (%)</th>
                                       <th styleCode="Rrule">Tadalafil Monotherapy<br/>(N=151)<br/>n  (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Peripheral edema</td>
                                       <td styleCode="Rrule">135 (45%)</td>
                                       <td styleCode="Rrule">58 (38%)</td>
                                       <td styleCode="Rrule">43 (28%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">125 (41%)</td>
                                       <td styleCode="Rrule">51 (34%)</td>
                                       <td styleCode="Rrule">53 (35%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nasal congestion</td>
                                       <td styleCode="Rrule">58 (19%)</td>
                                       <td styleCode="Rrule">25 (16%)</td>
                                       <td styleCode="Rrule">17 (11%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">53 (18%)</td>
                                       <td styleCode="Rrule">20 (13%)</td>
                                       <td styleCode="Rrule">24 (16%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anemia</td>
                                       <td styleCode="Rrule">44 (15%)</td>
                                       <td styleCode="Rrule">11 (7%)</td>
                                       <td styleCode="Rrule">17 (11%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspepsia</td>
                                       <td styleCode="Rrule">32 (11%)</td>
                                       <td styleCode="Rrule">5 (3%)</td>
                                       <td styleCode="Rrule">18 (12%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Bronchitis</td>
                                       <td styleCode="Rrule">31 (10%)</td>
                                       <td styleCode="Rrule">6 (4%)</td>
                                       <td styleCode="Rrule">13 (9%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Peripheral edema was more frequent on combination therapy; however, there was no notable difference observed in the incidence of peripheral edema in elderly patients (â¥65 years) versus younger patients (&lt;65 years) on combination therapy (44% vs. 45%) or Letairis monotherapy (37% vs. 39%) in AMBITION.</paragraph>
                              <paragraph>Treatment discontinuations due to adverse events while on randomized treatment were similar across treatment groups: 16% for Letairis + tadalafil, 14% for Letairis alone, and 13% for tadalafil alone. </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="96aa0fcb-76a0-4a52-bad3-3283531467d2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="underline">Use in Patients with Prior Endothelin Receptor Antagonist (ERA) Related Serum Liver Enzyme Abnormalities</content>
                                 </content>
                              </paragraph>
                              <paragraph>In an uncontrolled, open<content styleCode="bold">-</content>label study, 36 patients who had previously discontinued endothelin receptor antagonists (ERAs: bosentan, an investigational drug, or both) due to aminotransferase elevations &gt;3 Ã ULN were treated with Letairis. Prior elevations were predominantly moderate, with 64% of the ALT elevations &lt;5 Ã ULN, but 9 patients had elevations &gt;8 Ã ULN. Eight patients had been re-challenged with bosentan and/or the investigational ERA and all eight had a recurrence of aminotransferase abnormalities that required discontinuation of ERA therapy. All patients had to have normal aminotransferase levels on entry to this study. Twenty-five of the 36 patients were also receiving prostanoid and/or phosphodiesterase type 5 (PDE5) inhibitor therapy. Two patients discontinued early (including one of the patients with a prior 8 Ã ULN elevation). Of the remaining 34 patients, one patient experienced a mild aminotransferase elevation at 12 weeks on Letairis 5 mg that resolved with decreasing the dosage to 2.5 mg, and that did not recur with later escalations to 10 mg. With a median follow-up of 13 months and with 50% of patients increasing the dose of Letairis to 10 mg, no patients were discontinued for aminotransferase elevations. While the uncontrolled study design does not provide information about what would have occurred with re<content styleCode="bold">-</content>administration of previously used ERAs or show that Letairis led to fewer aminotransferase elevations than would have been seen with those drugs, the study indicates that Letairis may be tried in patients who have experienced asymptomatic aminotransferase elevations on other ERAs after aminotransferase levels have returned to normal.
          

</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="ecdab734-46ca-4362-be6e-e5d6001ea5d8"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions were identified during post-approval use of Letairis. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to estimate reliably the frequency or to establish a causal relationship to drug exposure: anemia requiring transfusion 
         
 
  <content styleCode="italics">[see 
          
  
   <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>] </content>heart failure (associated with fluid retention), symptomatic hypotension, and hypersensitivity (e.g., angioedema, rash).
        

</paragraph>
                        <paragraph>Elevations of liver aminotransferases (ALT, AST) have been reported with Letairis use; in most cases alternative causes of the liver injury could be identified (heart failure, hepatic congestion, hepatitis, alcohol use, hepatotoxic medications). Other endothelin receptor antagonists have been associated with elevations of aminotransferases, hepatotoxicity, and cases of liver failure 
         
 
  <content styleCode="italics">[see 
          
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="ce09bbf5-080c-4f3a-840d-3a0f5d5ed5c5"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Multiple dose coadministration of ambrisentan and cyclosporine resulted in an approximately 2-fold increase in ambrisentan exposure in healthy volunteers; therefore, limit the dose of ambrisentan to 5 mg once daily when coadministered with cyclosporine 
       
 
  <content styleCode="italics">[see 
        
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.
      

</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cyclosporine increases ambrisentan exposure; limit ambrisentan dose to 5 mg once daily (<linkHtml href="#S7">7</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="5c87872e-f58d-42a3-ae43-3061e5359f95"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Breastfeeding: Choose Letairis or breastfeeding (<linkHtml href="#S8.2">8.2</linkHtml>).</item>
                           <item> Not recommended in patients with moderate or severe hepatic impairment (<linkHtml href="#S8.7">8.7</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="a4d2d035-8b27-44fa-aba2-0ad32ea65808"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="f51578bb-e1b2-4215-81ae-c2cfa1f3aea8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on data from animal reproduction studies, Letairis may cause fetal harm, including birth defects and fetal death, when administered to a pregnant woman and is contraindicated during pregnancy. There are limited data on Letairis use in pregnant women. Available data from post-marketing reports and published literature over decades of use with endothelin receptor antagonists in the same class as Letairis have not identified an increased risk of major birth defects; however, these data are limited. Methodological limitations of these postmarketing reports and published literature include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and missing data. These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal endothelin receptor antagonist use. In animal reproduction studies, Letairis was teratogenic in rats and rabbits at doses which resulted in exposures of 3.5 and 1.7 times, respectively, the human dose of 10 mg per day
           
 
  <content styleCode="italics"> [see
            
  
   <linkHtml href="#Animal"> Animal Data</linkHtml>]</content>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential hazard to a fetus 
           
 
  <content styleCode="italics">[see 
            
  
   <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, 
            
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.
          

</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="bdf4ff02-728f-415a-b22f-d2f0cd86e85e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section ID="Animal">
                                 <id root="bcdfcf9b-f5f0-4066-a431-7a3d5a51f4a1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Letairis was teratogenic at oral dosages of â¥15 mg/kg/day (AUC 51.7 hâ¢Âµg/mL) in rats and â¥7 mg/kg/day (24.7 hâ¢Âµg/mL) in rabbits; it was not studied at lower dosages. These dosages are of 3.5 and 1.7 times, respectively, the human dose of 10 mg per day (14.8 hâ¢Âµg/mL) based on AUC. In both species, there were abnormalities of the lower jaw and hard and soft palate, malformation of the heart and great vessels, and failure of formation of the thymus and thyroid.</paragraph>
                                    <paragraph>A preclinical study in rats has shown decreased survival of newborn pups (mid and high dosages) and effects on testicle size and fertility of pups (high dosage) following maternal treatment with ambrisentan from late gestation through weaning. The mid and high dosages were 51 Ã, and 170 Ã (on a mg/m<sup>2</sup> body surface area basis) the maximum oral human dose of 10 mg and an average adult body weight of 70 kg. These effects were absent at a maternal dosage 17 Ã the human dose based on mg/m<sup>2</sup>.
            

</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="38152fa4-2a5d-461c-8453-826b1fa60b53"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="f6d99525-5822-4569-b253-3d2592b86231"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>It is not known whether ambrisentan is present in human milk. Because many drugs are present in human milk and because of the potential for serious adverse reactions in breastfed infants from Letairis, a decision should be made whether to discontinue breastfeeding or discontinue Letairis, taking into account the importance of the drug to the mother.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="55fd34d7-4b51-42ed-a072-906c303e624b"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="facf9bc3-2ab1-453a-b39a-1ea1a8a43bb3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Based on data from animal reproductive toxicity studies, ambrisentan may cause fetal harm, including birth defects and fetal death, when administered to a pregnant patient and is contraindicated during pregnancy <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify that patients who can become pregnant are not pregnant prior to initiating ambrisentan. The patient should contact their physician immediately for pregnancy testing if onset of menses is delayed or pregnancy is suspected. If the pregnancy test is positive, the physician and patient should discuss the risks to the pregnancy and the fetus.</paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Patients who can become pregnant who are using ambrisentan should use effective contraception prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with ambrisentan to prevent pregnancy <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3b86ca30-dcd2-42c9-80b8-ee5f00de2181"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="46a82767-6c5c-444d-a5d2-ffd54ebcfbaf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>In a 6-month study of another endothelin receptor antagonist, bosentan, 25 male patients with WHO functional class III and IV PAH and normal baseline sperm count were evaluated for effects on testicular function. There was a decline in sperm count of at least 50% in 25% of the patients after 3 or 6 months of treatment with bosentan. One patient developed marked oligospermia at 3 months, and the sperm count remained low with 2 follow-up measurements over the subsequent 6 weeks.</paragraph>
                                    <paragraph>Bosentan was discontinued and after 2 months the sperm count had returned to baseline levels. In 22 patients who completed 6 months of treatment, sperm count remained within the normal range and no changes in sperm morphology, sperm motility, or hormone levels were observed. Based on these findings and preclinical data 
             
 
  <content styleCode="italics">[see 
              
  
   <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]
             
 
  </content> from endothelin receptor antagonists, it cannot be excluded that endothelin receptor antagonists such as Letairis have an adverse effect on spermatogenesis. Counsel patients about the potential effects on fertility 
             
 
  <content styleCode="italics">[see 
              
  
   <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.
   </paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="ba84806a-5f4e-40e6-bbe5-91823c541531"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of Letairis in pediatric patients have not been established<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="2a857caf-52d8-4d42-8dc9-71c51e712ec4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Juvenile Animal Data</content>
                              </paragraph>
                              <paragraph>In juvenile rats administered ambrisentan orally once daily during postnatal day 7 to 26, 36, or 62, a decrease in brain weight (â3% to â8%) with no morphologic or neurobehavioral changes occurred after breathing sounds, apnea, and hypoxia were observed, at exposures approximately 1.8 to 7.0 times human pediatric exposures at 10 mg, based on AUC<content styleCode="italics">.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="df00865e-5460-4745-ba8f-bf6baee8a271"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In the two placebo-controlled clinical studies of Letairis, 21% of patients were â¥65 years old and 5% were â¥75 years old. The elderly (age â¥65 years) showed less improvement in walk distances with Letairis than younger patients did, but the results of such subgroup analyses must be interpreted cautiously. Peripheral edema was more common in the elderly than in younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="9a0198bf-db05-4108-83b4-bf6d73ee6fb9"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>The impact of renal impairment on the pharmacokinetics of ambrisentan has been examined using a population pharmacokinetic approach in PAH patients with creatinine clearances ranging between 20 and 150 mL/min. There was no significant impact of mild or moderate renal impairment on exposure to ambrisentan <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Dose adjustment of Letairis in patients with mild or moderate renal impairment is therefore not required. There is no information on the exposure to ambrisentan in patients with severe renal impairment.</paragraph>
                        <paragraph>The impact of hemodialysis on the disposition of ambrisentan has not been investigated.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="9ae911a5-6c18-45f6-b89b-fbe3057d2f5a"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="88841d3e-65df-4cd2-a8a9-6f4325c9645b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pre-existing Hepatic Impairment</content>
                              </paragraph>
                              <paragraph>The influence of pre-existing hepatic impairment on the pharmacokinetics of ambrisentan has not been evaluated. Because there is in vitro and in vivo evidence of significant metabolic and biliary contribution to the elimination of ambrisentan, hepatic impairment might be expected to have significant effects on the pharmacokinetics of ambrisentan 
           
 
  <content styleCode="italics">[see 
            
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)]</linkHtml>
                                 </content>. Letairis is not recommended in patients with moderate or severe hepatic impairment. There is no information on the use of Letairis in patients with mild pre-existing impaired liver function; however, exposure to ambrisentan may be increased in these patients.
          

</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5d961812-4bcf-4261-8508-1133a3c1c88b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elevation of Liver Transaminases</content>
                              </paragraph>
                              <paragraph>Other endothelin receptor antagonists (ERAs) have been associated with aminotransferase (AST, ALT) elevations, hepatotoxicity, and cases of liver failure 
           
 
  <content styleCode="italics">[see 
            
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>, 
            
  
   <linkHtml href="#S6.2">6.2)</linkHtml>].
           
 
  </content> In patients who develop hepatic impairment after Letairis initiation, the cause of liver injury should be fully investigated. Discontinue Letairis if elevations of liver aminotransferases are &gt;5 Ã ULN or if elevations are accompanied by bilirubin &gt;2 Ã ULN, or by signs or symptoms of liver dysfunction and other causes are excluded.
          

</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="507468ad-d26b-43e4-bb2a-bbff576300d4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There is no experience with overdosage of Letairis. The highest single dose of Letairis administered to healthy volunteers was 100 mg, and the highest daily dose administered to patients with PAH was 10 mg once daily. In healthy volunteers, single doses of 50 mg and 100 mg (5 to 10 times the maximum recommended dose) were associated with headache, flushing, dizziness, nausea, and nasal congestion. Massive overdosage could potentially result in hypotension that may require intervention.</paragraph>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3245cac6-7020-4fd3-a4bc-7d5fb0293b11"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Letairis contains ambrisentan, an endothelin receptor antagonist. The chemical name of
ambrisentan is (+)-(2<content styleCode="italics">S</content>)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid. It has a molecular formula of C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> and a molecular weight of 378.42 and has the following
structural formula:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1      Ambrisentan Structural Formula</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Ambrisentan is a white to off-white, crystalline solid. It is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in water and in aqueous solutions at low pH. Solubility increases in aqueous solutions at higher pH. In the solid state ambrisentan is very stable, is not hygroscopic, and is not light sensitive.</paragraph>
                  <paragraph>Letairis is available as 5 mg and 10 mg film-coated tablets for once daily oral administration. The tablets include the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. The tablets are film-coated with a coating material containing FD&amp;C Red #40 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink Letairis tablet contains 5 mg of ambrisentan. Each oval, deep pink Letairis tablet contains 10 mg of ambrisentan. Letairis tablets are unscored.</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="letairis-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="a90782bd-d78b-4660-a2e6-5e083e8eee1e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S12.1">
                     <id root="04de7a17-c3e4-42a2-8ea0-ad3230fa91aa"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ET<sub>A</sub> and ET<sub>B</sub>, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ET<sub>A </sub>are vasoconstriction and cell proliferation, while the predominant actions of ET<sub>B </sub>are vasodilation, antiproliferation, and ET-1 clearance.
        

</paragraph>
                        <paragraph>In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH.</paragraph>
                        <paragraph>Ambrisentan is a high-affinity (K<sub>i</sub>=0.011 nM) ET<sub>A</sub> receptor antagonist with a high selectivity for the ET<sub>A</sub> versus ET<sub>B </sub>receptor (&gt;4000-fold). The clinical impact of high selectivity for ET<sub>A </sub>is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="0e843801-60b2-45bd-a5ab-18ca5d8c71d8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="fb3d1b81-d92e-41bc-822e-8f6f4276b051"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology </content>
                              </paragraph>
                              <paragraph>In a randomized, positive- and placebo-controlled, parallel-group study, healthy subjects received either Letairis 10 mg daily followed by a single dose of 40 mg, placebo followed by a single dose of moxifloxacin 400 mg, or placebo alone. Letairis 10 mg daily had no significant effect on the QTc interval. The 40 mg dose of Letairis increased mean QTc at t<sub>max</sub> by 5 ms with an upper 95% confidence limit of 9 ms. For patients receiving Letairis 5â10 mg daily and not taking metabolic inhibitors, no significant QT prolongation is expected.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8a713356-cbe0-4ac2-9787-36a5f2f4103a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">N-terminal pro-B-type natriuretic peptide (NT-proBNP) </content>
                              </paragraph>
                              <paragraph>In AMBITION 
           
 
  <content styleCode="italics">[see 
            
  
   <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>, the decrease in NT-proBNP in patients on Letairis plus tadalafil was observed early (Week 4) and was sustained, with a reduction of 63% on Letairis plus tadalafil, 50% on Letairis alone, and 41% on tadalafil alone at Week 24.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="6f6b2edb-d205-4cdd-a295-bb6ac2dd09a3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of ambrisentan (S-ambrisentan) in healthy subjects is dose proportional. The absolute bioavailability of ambrisentan is not known. Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients. Food does not affect its bioavailability. In vitro studies indicate that ambrisentan is a substrate of P-gp. Ambrisentan is highly bound to plasma proteins (99%). The elimination of ambrisentan is predominantly by non-renal pathways, but the relative contributions of metabolism and biliary elimination have not been well characterized. In plasma, the AUC of 4-hydroxymethyl ambrisentan accounts for approximately 4% relative to parent ambrisentan AUC. The in vivo inversion of S-ambrisentan to R-ambrisentan is negligible. The mean oral clearance of ambrisentan is 38 mL/min and 19 mL/min in healthy subjects and in PAH patients, respectively. Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="8c8761b2-5ead-438a-9636-b8cc9860a324"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="328cfe05-fa86-481f-a6c1-1b3214482b91"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro</content>
                                       <content styleCode="italics"> Studies</content>
                                    </paragraph>
                                    <paragraph>Studies with human liver tissue indicate that ambrisentan is metabolized by CYP3A, CYP2C19, and uridine 5'-diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S, and 1A3S. In vitro studies suggest that ambrisentan is a substrate of the Organic Anion Transporting Polypeptides OATP1B1 and OATP1B3, and P-glycoprotein (P-gp). Drug interactions might be expected because of these factors; however, a clinically relevant interaction has been demonstrated only with cyclosporine 
             
 
  <content styleCode="italics">[see 
              
  
   <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. In vitro studies found ambrisentan to have little to no inhibition of human hepatic transporters. Ambrisentan demonstrated weak dose-dependent inhibition of OATP1B1, OATP1B3, and NTCP (IC<sub>50</sub> of 47 ÂµM, 45 ÂµM, and approximately 100 ÂµM, respectively) and no transporter-specific inhibition of BSEP, BRCP, P-gp, or MRP2. Ambrisentan does not inhibit or induce drug metabolizing enzymes at clinically relevant concentrations.
            

</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="013b145b-f785-45c5-9816-95fb5073f742"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vivo</content>
                                       <content styleCode="italics"> Studies</content>
                                    </paragraph>
                                    <paragraph>The effects of other drugs on ambrisentan pharmacokinetics and the effects of ambrisentan on the exposure to other drugs are shown in Figure 2 and Figure 3, respectively.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Figure 2  Effects of Other Drugs on Ambrisentan Pharmacokinetics</content>
                                    </paragraph>
                                    <renderMultiMedia referencedObject="MM2"/>
                                    <paragraph>* Omeprazole: based on population pharmacokinetic analysis in PAH patients</paragraph>
                                    <paragraph>** Rifampin: AUC and C<sub>max</sub> were measured at steady-state. On Day 3 of coadministration a transient 2-fold increase in AUC was noted that was no longer evident by Day 7. Day 7 results are presented.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Figure 3  Effects of Ambrisentan on Other Drugs</content>
                                    </paragraph>
                                    <renderMultiMedia referencedObject="MM3"/>
                                    <paragraph>* Active metabolite of mycophenolate mofetil</paragraph>
                                    <paragraph>** GMR (95% CI) for INR</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                                 <component>
                                    <observationMedia ID="MM2">
                                       <text>Figure 2</text>
                                       <value mediaType="image/jpeg" xsi:type="ED">
                                          <reference value="letairis-02.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                                 <component>
                                    <observationMedia ID="MM3">
                                       <text>Figure 3</text>
                                       <value mediaType="image/jpeg" xsi:type="ED">
                                          <reference value="letairis-03.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="bcb95d2c-e31f-4dd1-8b55-bbe6dc7eecee"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S13.1">
                     <id root="5b7d6ff1-56e5-44f1-822b-f15825b07600"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Oral carcinogenicity studies of up to two years duration were conducted at starting doses of 10, 30, and 60 mg/kg/day in rats (8 to 48 times the maximum recommended human dose [MRHD] on a mg/m<sup>2</sup> basis) and at 50, 150, and 250 mg/kg/day in mice (28 to 140 times the MRHD). In the rat study, the high- and mid-dose male and female groups had their doses lowered to 40 and 20 mg/kg/day, respectively, in week 51 because of effects on survival. The high-dose males and females were taken off drug completely in weeks 69 and 93, respectively. The only evidence of ambrisentan-related carcinogenicity was a positive trend in male rats, for the combined incidence of benign basal cell tumor and basal cell carcinoma of skin/subcutis in the mid-dose group (high-dose group excluded from analysis), and the occurrence of mammary fibroadenomas in males in the high-dose group. In the mouse study, high-dose male and female groups had their doses lowered to 150 mg/kg/day in week 39 and were taken off drug completely in week 96 (males) or week 76 (females). In mice, ambrisentan was not associated with excess tumors in any dosed group.
        

</paragraph>
                        <paragraph>Positive findings of clastogenicity were detected, at drug concentrations producing moderate to high toxicity, in the chromosome aberration assay in cultured human lymphocytes. There was no evidence for genetic toxicity of ambrisentan when tested in vitro in bacteria (Ames test) or in vivo in rats (micronucleus assay, unscheduled DNA synthesis assay).</paragraph>
                        <paragraph>The development of testicular tubular atrophy and impaired fertility has been linked to the chronic administration of endothelin receptor antagonists in rodents. Testicular tubular degeneration was observed in rats treated with ambrisentan for two years at doses â¥10 mg/kg/day (8-fold MRHD). Increased incidences of testicular findings were also observed in mice treated for two years at doses â¥50 mg/kg/day (28-fold MRHD). Effects on sperm count, sperm morphology, mating performance, and fertility were observed in fertility studies in which male rats were treated with ambrisentan at oral doses of 300 mg/kg/day (236-fold MRHD). At doses of â¥10 mg/kg/day, observations of testicular histopathology in the absence of fertility and sperm effects were also present.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="6647c261-a36b-4689-a05e-bc8298912ae6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S14.1">
                     <id root="ea83dca2-e567-4411-9518-ad928b79374e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Pulmonary Arterial Hypertension (PAH)</title>
                     <text>
                        <paragraph>Two 12-week, randomized, double-blind, placebo-controlled, multicenter studies were conducted in 393 patients with PAH (WHO Group 1). The two studies were identical in design except for the doses of Letairis and the geographic region of the investigational sites. ARIES-1 compared once-daily doses of 5 mg and 10 mg Letairis to placebo, while ARIES-2 compared once-daily doses of 2.5 mg and 5 mg Letairis to placebo. In both studies, Letairis or placebo was added to current therapy, which could have included a combination of anticoagulants, diuretics, calcium channel blockers, or digoxin, but not epoprostenol, treprostinil, iloprost, bosentan, or sildenafil. The primary study endpoint was 6-minute walk distance. In addition, clinical worsening, WHO functional class, dyspnea, and SF-36<sup>Â®</sup> Health Survey were assessed.</paragraph>
                        <paragraph>Patients had idiopathic or heritable PAH (64%) or PAH associated with connective tissue diseases (32%), HIV infection (3%), or anorexigen use (1%). There were no patients with PAH associated with congenital heart disease.</paragraph>
                        <paragraph>Patients had WHO functional class I (2%), II (38%), III (55%), or IV (5%) symptoms at baseline. The mean age of patients was 50 years, 79% of patients were female, and 77% were Caucasian.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="8b57cd83-f298-4e53-a9c8-c8fe1544cbd2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Submaximal Exercise Ability</content>
                              </paragraph>
                              <paragraph>Results of the 6-minute walk distance at 12 weeks for the ARIES-1 and ARIES-2 studies are shown in Table 3 and Figure 4.</paragraph>
                              <table width="75%" ID="Table3">
                                 <caption>Table 3    Changes from Baseline in 6-Minute Walk Distance (meters) (ARIES-1 and ARIES-2)</caption>
                                 <col width="22%" align="left" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2"/>
                                       <th colspan="3" styleCode="Rrule">ARIES-1</th>
                                       <th colspan="3" styleCode="Rrule">ARIES-2</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">Placebo
              
    
     <br/>(N=67)
             
   
    </th>
                                       <th styleCode="Rrule">5 mg
              
    
     <br/>(N=67)
             
   
    </th>
                                       <th styleCode="Rrule">10 mg
              
    
     <br/>(N=67)
             
   
    </th>
                                       <th styleCode="Rrule">Placebo
              
    
     <br/>(N=65)
             
   
    </th>
                                       <th styleCode="Rrule">2.5 mg
              
    
     <br/>(N=64)
             
   
    </th>
                                       <th styleCode="Rrule">5 mg
              
    
     <br/>(N=63)
             
   
    </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="7" valign="top">Mean Â± standard deviation</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Baseline</td>
                                       <td styleCode="Rrule">342 Â± 73</td>
                                       <td styleCode="Rrule">340 Â± 77</td>
                                       <td styleCode="Rrule">342 Â± 78</td>
                                       <td styleCode="Rrule">343 Â± 86</td>
                                       <td styleCode="Rrule">347 Â± 84</td>
                                       <td styleCode="Rrule">355 Â± 84</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Mean change from baseline</td>
                                       <td styleCode="Rrule">-8 Â± 79</td>
                                       <td styleCode="Rrule">23 Â± 83</td>
                                       <td styleCode="Rrule">44 Â± 63</td>
                                       <td styleCode="Rrule">-10 Â± 94</td>
                                       <td styleCode="Rrule">22 Â± 83</td>
                                       <td styleCode="Rrule">49 Â± 75</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Placebo-adjusted mean change from baseline</td>
                                       <td styleCode="Rrule">_</td>
                                       <td styleCode="Rrule">31</td>
                                       <td styleCode="Rrule">51</td>
                                       <td styleCode="Rrule">_</td>
                                       <td styleCode="Rrule">32</td>
                                       <td styleCode="Rrule">59</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Placebo-adjusted median change from baseline</td>
                                       <td styleCode="Rrule">_</td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">39</td>
                                       <td styleCode="Rrule">_</td>
                                       <td styleCode="Rrule">30</td>
                                       <td styleCode="Rrule">45</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">p-value<footnote ID="K3304">p-values are Wilcoxon rank sum test comparisons of Letairis to placebo at Week 12 stratified by idiopathic or heritable PAH and non-idiopathic, non-heritable PAH patients</footnote>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">_</td>
                                       <td styleCode="Rrule">0.008</td>
                                       <td styleCode="Rrule">&lt;0.001</td>
                                       <td styleCode="Rrule" valign="bottom">_</td>
                                       <td styleCode="Rrule">0.022</td>
                                       <td styleCode="Rrule">&lt;0.001</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 4         Mean Change in 6-Minute Walk Distance (ARIES-1 and ARIES-2)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM4"/>
                              </paragraph>
                              <paragraph>Mean change from baseline in 6-minute walk distance in the placebo and Letairis groups.
           
 
  <br/>Values are expressed as mean Â± standard error of the mean.
          

</paragraph>
                              <paragraph>In both studies, treatment with Letairis resulted in a significant improvement in 6-minute walk distance for each dose of Letairis and the improvements increased with dose. An increase in 6-minute walk distance was observed after 4 weeks of treatment with Letairis, with a dose-response observed after 12 weeks of treatment. Improvements in walk distance with Letairis were smaller for elderly patients (age â¥65) than younger patients and for patients with secondary PAH than for patients with idiopathic or heritable PAH. The results of such subgroup analyses must be interpreted cautiously.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 4</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="letairis-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5fad60a3-3354-4db0-8575-2fcfc13118fe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Clinical Worsening</content>
                              </paragraph>
                              <paragraph>Time to clinical worsening of PAH was defined as the first occurrence of death, lung transplantation, hospitalization for PAH, atrial septostomy, study withdrawal due to the addition of other PAH therapeutic agents, or study withdrawal due to early escape. Early escape was defined as meeting two or more of the following criteria: a 20% decrease in the 6-minute walk distance; an increase in WHO functional class; worsening right ventricular failure; rapidly progressing cardiogenic, hepatic, or renal failure; or refractory systolic hypotension. The clinical worsening events during the 12-week treatment period of the Letairis clinical trials are shown in Table 4 and Figure 5.</paragraph>
                              <table width="75%">
                                 <caption>Table 4    Time to Clinical Worsening (ARIES-1 and ARIES-2)</caption>
                                 <col width="32%" align="left" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th rowspan="2" styleCode="Lrule Rrule"/>
                                       <th colspan="2" styleCode="Rrule">ARIES-1</th>
                                       <th colspan="2" styleCode="Rrule">ARIES-2</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th align="center" styleCode="Rrule">Placebo
              
    
     <br/>(N=67)
             
   
    </th>
                                       <th styleCode="Rrule">Letairis
              
    
     <br/>(N=134)
             
   
    </th>
                                       <th styleCode="Rrule">Placebo
              
    
     <br/>(N=65)
             
   
    </th>
                                       <th styleCode="Rrule">Letairis
              
    
     <br/>(N=127)
             
   
    </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="5" valign="top">Intention-to-treat population. 
              
    
     <br/>Note: Patients may have had more than one reason for clinical worsening.
              
    
     <br/>Nominal p-values
             
   
    </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Clinical worsening, no. (%)</td>
                                       <td styleCode="Rrule">7 (10%)</td>
                                       <td styleCode="Rrule">4 (3%)</td>
                                       <td styleCode="Rrule">13 (22%)</td>
                                       <td styleCode="Rrule">8 (6%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hazard ratio</td>
                                       <td styleCode="Rrule" valign="bottom">_</td>
                                       <td styleCode="Rrule">0.28</td>
                                       <td styleCode="Rrule" valign="bottom">_</td>
                                       <td styleCode="Rrule">0.30</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">p-value, Log-rank test</td>
                                       <td styleCode="Rrule" valign="bottom">_</td>
                                       <td styleCode="Rrule">0.030</td>
                                       <td styleCode="Rrule" valign="bottom">_</td>
                                       <td styleCode="Rrule">0.005</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>There was a significant delay in the time to clinical worsening for patients receiving Letairis compared to placebo. Results in subgroups such as the elderly were also favorable.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 5         Time to Clinical Worsening (ARIES-1 and ARIES-2)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM5"/>
                              </paragraph>
                              <paragraph>Time from randomization to clinical worsening with Kaplan-Meier estimates of the proportions of patients without events in ARIES-1 and ARIES-2.</paragraph>
                              <paragraph>p-values shown are the log-rank comparisons of Letairis to placebo stratified by idiopathic or heritable PAH and non-idiopathic, non-heritable PAH patients.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <observationMedia ID="MM5">
                                 <text>Figure 5</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="letairis-05.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="5f6bad2e-1cc0-4656-b880-24e4e1a10b41"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Combination Treatment of PAH</title>
                     <text>
                        <paragraph>In a randomized, double-blind, active-controlled trial (AMBITION), 605 patients with WHO Functional Class II or III PAH were randomized 2:1:1 to once daily Letairis plus tadalafil or to Letairis or tadalafil alone. Treatment was initiated with Letairis 5 mg and tadalafil 20 mg.  If tolerated, tadalafil was increased to 40 mg at 4 weeks and Letairis was increased to 10 mg at 8 weeks.</paragraph>
                        <paragraph>The primary endpoint was time to first occurrence of (a) death, (b) hospitalization for worsening PAH, (c) &gt;15% decrease from baseline in 6MWD combined with WHO Functional Class III or IV symptoms sustained over 14 days (short term clinical worsening), or (d) reduction in 6MWD sustained over 14 days combined with WHO Functional Class III or IV symptoms sustained over 6 months (inadequate long term clinical response).</paragraph>
                        <paragraph>Patients had idiopathic PAH (55%), heritable PAH (3%), or PAH associated with connective tissue diseases, congenital heart disease, stable HIV infection, or drugs or toxins (APAH, 43%). Median time from diagnosis to first study drug administration was 25 days. Approximately 32% and 68% of patients were in WHO Functional Class II and III, respectively. The mean patient age was 55.7 years (34% were â¥65 years old). Most patients were white (90%) and female (76%); 45% were North American.</paragraph>
                        <paragraph>Principal results are shown in Figures 6 and 7.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 6               Time to Primary Endpoint Event (AMBITION)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM6"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 7               Primary Endpoint Events and First Occurrences of Each Component at Any Time (AMBITION) </content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM7"/>
                        </paragraph>
                        <paragraph>The treatment effect of Letairis plus tadalafil compared with individual monotherapy on time to first primary endpoint event was consistent across subgroups. (Figure 8).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 8               Primary Endpoint by Subgroups (AMBITION)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM8"/>
                        </paragraph>
                        <paragraph>Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over interpreted.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <observationMedia ID="MM6">
                           <text>Figure 6</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="letairis-06.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM7">
                           <text>Figure 7</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="letairis-07.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM8">
                           <text>Figure 8</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="letairis-08.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <section>
                           <id root="4100851f-3344-4b22-a4d3-d358f7a5dfe3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Exercise Ability</content>
                              </paragraph>
                              <paragraph>Results of the 6MWD at 24 weeks for the AMBITION study are shown in Table 5 and Figure 9.</paragraph>
                              <table width="65%" ID="Table5">
                                 <caption>Table 5 6-Minute Walk Distance at Week 24 (meters)<footnote ID="K3585">Missing values at Week 24 were imputed using Worst Rank scores for patients with an adjudicated clinical failure event of death or hospitalization, and Last Observed Carried Forward otherwise.</footnote> (AMBITION)</caption>
                                 <col width="28%" align="left" valign="middle"/>
                                 <col width="24%" align="center" valign="middle"/>
                                 <col width="24%" align="center" valign="middle"/>
                                 <col width="24%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Letairis + Tadalafil
              
    
     <br/>(N=302)
             
   
    </th>
                                       <th styleCode="Rrule">Letairis Monotherapy
              
    
     <br/>(N=152)
             
   
    </th>
                                       <th styleCode="Rrule">Tadalafil  Monotherapy
              
    
     <br/>(N=151)
             
   
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Baseline (median)</td>
                                       <td styleCode="Rrule">356</td>
                                       <td styleCode="Rrule">366</td>
                                       <td styleCode="Rrule">352</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Change from baseline  (median)</td>
                                       <td styleCode="Rrule">43</td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">22</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median difference from Letairis + Tadalafil
              
    
     <br/>(95% CI)
             
   
    </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">24
              
    
     <br/>(11, 37)
             
   
    </td>
                                       <td styleCode="Rrule">20
              
    
     <br/>(8, 32)
             
   
    </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">P-Value</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">0.0004</td>
                                       <td styleCode="Rrule">0.0016</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 9         Median Change in 6-Minute Walk Distance (meters) in AMBITION </content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM9"/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <observationMedia ID="MM9">
                                 <text>Figure 9</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="letairis-09.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d4a711a7-11cb-428c-8dca-4d46cf62d646"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Long-term Treatment of PAH </title>
                     <text>
                        <paragraph>In long-term follow-up of patients who were treated with Letairis (2.5 mg, 5 mg, or 10 mg once daily) in the two pivotal studies and their open-label extension (N=383), Kaplan-Meier estimates of survival at 1, 2, and 3 years were 93%, 85%, and 79%, respectively. Of the patients who remained on Letairis for up to 3 years, the majority received no other treatment for PAH. These uncontrolled observations do not allow comparison with a group not given Letairis and cannot be used to determine the long-term effect of Letairis on mortality.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="05cd6eb5-b87f-421b-8f2c-363e1f734c3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Adverse Effects in Idiopathic Pulmonary Fibrosis (IPF)</title>
                     <text>
                        <paragraph>A randomized controlled study in patients with IPF, with or without pulmonary hypertension (WHO Group 3), compared Letairis (N=329) to placebo (N=163). The study was terminated after 34 weeks for lack of efficacy, and was found to demonstrate a greater risk of disease progression or death on Letairis. More patients taking Letairis died (8% vs. 4%), had a respiratory hospitalization (13% vs. 6%), and had a decrease in FVC/DLCO (17% vs. 12%) <content styleCode="italics">[see <linkHtml href="#S4.2">Contraindications (4.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="579a1ea1-62ef-43c3-b2bd-1a382302382e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Letairis film<content styleCode="bold">-</content>coated tablets are supplied as follows:
      

</paragraph>
                  <table width="75%">
                     <col width="26%" align="center" valign="middle"/>
                     <col width="22%" align="center" valign="middle"/>
                     <col width="22%" align="center" valign="middle"/>
                     <col width="30%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule">Tablet Strength</th>
                           <th styleCode="Rrule">Package Configuration</th>
                           <th styleCode="Rrule">NDC No.</th>
                           <th styleCode="Rrule">Description of Tablet;
          
    
     <br/>Debossed on Tablet;
          
    
     <br/>Size
         
   
    </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="4" styleCode="Lrule Rrule Botrule">5 mg</td>
                           <td styleCode="Rrule Botrule">30 count blister</td>
                           <td styleCode="Rrule Botrule">61958<content styleCode="bold">-</content>0801<content styleCode="bold">-</content>2
         
   
    </td>
                           <td rowspan="4" styleCode="Rrule" valign="top">Square convex; pale pink;<br/>"5" on side 1 and "GSI" on side 2;<br/>6.6 mm Square
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule">30 count bottle</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0801<content styleCode="bold">-</content>1
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule">10 count blister</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0801<content styleCode="bold">-</content>3
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule">10 count bottle</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0801<content styleCode="bold">-</content>5
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td rowspan="4" styleCode="Lrule Rrule">10 mg</td>
                           <td styleCode="Rrule">30 count blister</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0802<content styleCode="bold">-</content>2
         
   
    </td>
                           <td rowspan="4" styleCode="Rrule Toprule" valign="top">Oval convex; deep pink;<br/>"10" on side 1 and "GSI" on side 2;<br/>9.8 mm Ã 4.9 mm Oval
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule">30 count bottle</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0802<content styleCode="bold">-</content>1
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule">10 count blister</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0802<content styleCode="bold">-</content>3
         
   
    </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule">10 count bottle</td>
                           <td styleCode="Rrule">61958<content styleCode="bold">-</content>0802<content styleCode="bold">-</content>5
         
   
    </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <section>
                     <id root="ee5e4472-b3f8-461f-a18b-3c54f460e5d0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 25Â° C (77Â° F); excursions permitted to 15<content styleCode="bold">â</content>30Â° C (59<content styleCode="bold">â</content>86Â° F) <content styleCode="italics">[see USP controlled room temperature]</content>. Store Letairis in its original packaging.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="25820e86-715f-4afc-b160-fbe6ca0aa4b7"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients to read the FDA-approved patient labeling (<linkHtml href="#SMG">Medication Guide</linkHtml>).</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <section>
                     <id root="9f087431-5bcf-4172-93bb-92c80579df78"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Embryo-fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Instruct patients on the risk of fetal harm when Letairis is used in pregnancy <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>. Instruct females of reproductive potential to immediately contact their physician if they suspect they may be pregnant.</paragraph>
                        <paragraph>
              Educate and counsel patients who can become pregnant about the need to use effective contraception prior to treatment with Letairis, during treatment, and for one month after treatment discontinuation <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>. Patients who can become pregnant should have a negative pregnancy test prior to treatment with Letairis <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.
                                                  </paragraph>
                        <paragraph>
             Counsel patients who can become pregnant about pregnancy planning and prevention, including emergency contraception, or designate counseling by another healthcare provider trained in contraceptive counseling <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>]</content>.
                                                  </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0e2743b5-ac37-401c-859c-098e8af23074"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Hepatic Effects</content>
                        </paragraph>
                        <paragraph>Advise patients of the symptoms of potential liver injury and instruct them to report any of these symptoms to their physician.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7846cd1e-d545-4af1-a3cc-ebeefce9f202"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Hematological Change</content>
                        </paragraph>
                        <paragraph>Advise patients of the importance of hemoglobin testing.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8bc9a303-52c5-41dc-8b6a-e8efcd7113e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Other Risks Associated with Letairis</content>
                        </paragraph>
                        <paragraph>Instruct patients that the risks associated with Letairis also include the following:</paragraph>
                        <list listType="unordered">
                           <item>Decreases in sperm count</item>
                           <item>Fluid overload</item>
                        </list>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="33a9ced7-6990-44d3-a56b-a2523ba6fd7e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Administration</content>
                        </paragraph>
                        <paragraph>Advise patients not to split, crush, or chew tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="09222b04-0c52-4bb3-968b-6350656f03de"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Gilead Sciences, Inc., Foster City, CA 94404</paragraph>
                  <paragraph>Letairis is a registered trademark of Gilead Sciences, Inc. Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. Other brands noted herein are the property of their respective owners.</paragraph>
                  <paragraph>Â© 2025 Gilead Sciences, Inc.</paragraph>
                  <paragraph>GS22-081-018</paragraph>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section ID="SMG">
               <id root="37fa54d8-7f41-44d5-a7ef-5d8938575a23"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="40%" align="left" valign="top"/>
                     <col width="40%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td colspan="2">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" valign="top">Revised April 2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="3" align="center" styleCode="Lrule Rrule">
                              <content styleCode="bold">Medication Guide<br/>Letairis<sup>Â®</sup> (le-TAIR-is)<br/>(ambrisentan) tablets</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">Read this Medication Guide before you start taking Letairis and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <paragraph ID="Whatis">
                                 <content styleCode="bold">What is the most important information I should know about Letairis?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Serious birth defects.
             
       
        <br/>Letairis can cause serious birth defects if taken during pregnancy. 
            
      
       </content>
                                    <list listType="unordered">
                                       <item>
                                          <content styleCode="bold">Females should not be pregnant when they start taking Letairis or become pregnant during treatment with Letairis.  </content>
                                       </item>
                                       <item>Females who are able to get pregnant should have a negative pregnancy test before beginning treatment with  Letairis. Talk to your doctor about your menstrual cycle. Your doctor will decide when to do a pregnancy test, and will order a pregnancy test for you depending on your menstrual cycle.
              
        
         <list listType="unordered">
                                             <item>Females who 
                
          
           <content styleCode="bold">are able</content> to get pregnant are females who:
                
          
           <list listType="unordered" styleCode="Disc">
                                                   <item>have entered puberty, even if they have not started their menstrual period, 
                  
            
             <content styleCode="bold">and</content>
                                                   </item>
                                                   <item>have a uterus, 
                  
            
             <content styleCode="bold">and</content>
                                                   </item>
                                                   <item>have not gone through menopause. Menopause means that you have not had a menstrual period for at least 12 months for natural reasons, or that you have had your ovaries removed.</item>
                                                </list>
                                             </item>
                                             <item>Females who 
                
          
           <content styleCode="bold">are not able</content> to get pregnant are females who:
                
          
           <list listType="unordered" styleCode="Disc">
                                                   <item>have not yet entered puberty, 
                  
            
             <content styleCode="bold">or</content>
                                                   </item>
                                                   <item>do not have a uterus, 
                  
            
             <content styleCode="bold">or</content>
                                                   </item>
                                                   <item>have gone through menopause. Menopause means that you have not had a menstrual period for at least 12 months for natural reasons, or that you have had your ovaries removed, 
                  
            
             <content styleCode="bold">or</content>
                                                   </item>
                                                   <item>who are infertile for any other medical reason and this infertility is permanent and cannot be reversed</item>
                                                </list>
                                             </item>
                                          </list>
                                       </item>
                                    </list>
                                    <content styleCode="bold">Females who are able to get pregnant should use effective contraception before beginning Letairis, during treatment with Letairis, and for one month after stopping Letairis because the medicine may still be in the body.</content>
                                    <list listType="unordered">
                                       <item>Talk with your doctor or gynecologist (a doctor who specializes in female reproduction) to find out about options for acceptable forms of birth control that you may use to prevent pregnancy during treatment with Letairis.</item>
                                       <item>If you decide that you want to change the form of birth control that you use, talk with your doctor or gynecologist to be sure that you choose another acceptable form of birth control.</item>
                                    </list>
                                    <list listType="unordered">
                                       <item>
                                          <content styleCode="bold">Do not have unprotected sex. Talk to your doctor or pharmacist right away if you have unprotected sex or if you think your birth control has failed. Your doctor may tell you to use emergency birth control.</content>
                                       </item>
                                       <item>
                                          <content styleCode="bold">Tell your doctor right away if you miss a menstrual period or think you may be pregnant for any reason.</content>
                                       </item>
                                    </list>
                                 </item>
                              </list>If you are the parent or caregiver of a female child who started taking Letairis before reaching puberty, you should check your child regularly to see if she is developing signs of puberty. Tell your doctor right away if you notice that she is developing breast buds or pubic hair. Your doctor should decide if your child has reached puberty<content styleCode="bold">. Your child may reach puberty before having her first menstrual period.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is Letairis?</content>
                              <list listType="unordered">
                                 <item>Letairis is a prescription medicine used to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs.</item>
                                 <item>Letairis can improve your ability to exercise and it can help slow down the worsening of your physical condition and symptoms.</item>
                                 <item>When taken with tadalafil, Letairis is used to reduce the risk of your disease progressing, to reduce the risk of hospitalization due to worsening pulmonary arterial hypertension (PAH), and to improve your ability to exercise. </item>
                                 <item>It is not known if Letairis is safe and effective in children.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">Who should not take Letairis?
           
     
      <br/>Do not take Letairis if:
          
    
     </content>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">you are pregnant, plan to become pregnant, or become pregnant during treatment with Letairis. Letairis can cause serious birth defects.</content> (See 
            
      
       <content styleCode="bold">â<linkHtml href="#Whatis">What is the most important information I should know about Letairis?</linkHtml>â</content>)
            
      </item>
                                 <item>you have a condition called Idiopathic Pulmonary Fibrosis (IPF)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I tell my doctor before taking Letairis?
           
     
      <br/>Before you take Letairis, tell your doctor if you:
          
    
     </content>
                              <list listType="unordered">
                                 <item>have been told that you have a low red blood cell level (anemia)</item>
                                 <item>have liver problems</item>
                                 <item>have any other medical conditions</item>
                              </list>
                              <content styleCode="bold">Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</content> Letairis and other medicines may affect each other, causing side effects. Do not start any new medicines until you check with your doctor.
          
    
     <br/>
                              <content styleCode="bold">Especially tell your doctor if you take the medicine cyclosporine (Gengraf, Neoral, Sandimmune).</content> Your doctor may need to change your dose of Letairis. 
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take Letairis?</content>
                              <list listType="unordered">
                                 <item>Take Letairis exactly as your doctor tells you to take it. Do not stop taking Letairis unless your doctor tells you to stop.</item>
                                 <item>You can take Letairis with or without food.</item>
                                 <item>Do not split, crush or chew Letairis tablets.</item>
                                 <item>It will be easier to remember to take Letairis if you take it at the same time each day.</item>
                                 <item>If you take more than your regular dose of Letairis, call your doctor right away.</item>
                                 <item>If you miss a dose, take it as soon as you remember that day. Take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I avoid while taking Letairis?</content>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Do not get pregnant</content> while taking Letairis. (See the serious birth defects section of the Medication Guide above called 
            
      
       <content styleCode="bold">â<linkHtml href="#Whatis">What is the most important information I should know about Letairis?</linkHtml>â</content>) If you miss a menstrual period, or think you might be pregnant, call your doctor right away.
           
     
      </item>
                                 <item>
                                    <content styleCode="bold">It is not known if Letairis passes into your breast milk. You should not breastfeed</content> if you are taking Letairis. Talk to your doctor about the best way to feed your baby if you take Letairis.
           
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of Letairis?
           
     
      <br/>Letairis can cause serious side effects including: 
          
    
     </content>
                              <list listType="unordered">
                                 <item>See 
            
      
       <content styleCode="bold">â<linkHtml href="#Whatis">What is the most important information I should know about Letairis?</linkHtml>â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Swelling all over the body</content> (fluid retention) can happen within weeks after starting Letairis. Tell your doctor right away if you have any unusual weight gain, tiredness, or trouble breathing while taking Letairis. These may be symptoms of a serious health problem. You may need to be treated with medicine or need to go to the hospital.
           
     
      </item>
                                 <item>
                                    <content styleCode="bold">Decreased sperm count.</content> Decreased sperm counts have happened in some men taking a medicine that is like Letairis. A decreased sperm count may affect the ability to father a child. Tell your doctor if being able to have children is important to you. 
           
     
      </item>
                                 <item>
                                    <content styleCode="bold">Low red blood cell levels</content> (anemia) can happen during the first weeks after starting Letairis. If this happens, you may need a blood transfusion. Your doctor will do blood tests to check your red blood cells before starting Letairis. Your doctor may also do these tests during treatment with Letairis.
           
     
      </item>
                              </list>
                              <content styleCode="bold">The most common side effects of Letairis include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>swelling of hands, legs, ankles and feet (peripheral edema)</item>
                                 <item>stuffy nose (nasal congestion)</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>inflamed nasal passages (sinusitis)</item>
                                 <item>hot flashes or getting red in the face (flushing)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">Some medicines that are like Letairis can cause liver problems. Tell your doctor if you get any of these symptoms of a liver problem while taking Letairis:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>loss of appetite</item>
                                 <item>nausea or vomiting</item>
                                 <item>fever</item>
                                 <item>achiness</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>generally do not feel well</item>
                                 <item>pain in the upper right stomach (abdominal) area</item>
                                 <item>yellowing of your skin or the whites of your eyes</item>
                                 <item>dark urine</item>
                                 <item>itching</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Letairis. For more information, ask your doctor or pharmacist.
          
    
     <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store Letairis?</content>
                              <br/>Store Letairis at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C), in the package it comes in.
          
    
     <br/>
                              <content styleCode="bold">Keep Letairis and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of Letairis</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Letairis for a condition for which it was not prescribed. Do not give Letairis to other people, even if they have the same symptoms that you have. It may harm them. 
          
    
     <br/>This Medication Guide summarizes the most important information about Letairis. If you would like more information, ask your doctor. You can ask your doctor or pharmacist for information about Letairis that is written for health professionals.  
         
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in Letairis?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient</content>: ambrisentan
          
    
     <br/>
                              <content styleCode="bold">Inactive Ingredients:</content> croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose.  The tablets are film-coated with a coating material containing FD&amp;C Red #40 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
          
    
     <br/>Gilead Sciences, Inc., Foster City, CA 94404
          
    
     <br/>Letairis is a registered trademark of Gilead Sciences, Inc.  Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.  Other brands noted herein are the property of their respective owners.
          
    
     <br/>Â© 2025 Gilead Sciences, Inc.
          
    
     <br/>GS22-081-018
          
    
     <br/>For more information call 1-866-664-5327 or go to <linkHtml href="www.letairis.com">www.letairis.com</linkHtml> or <linkHtml href="www.gilead.com">www.gilead.com</linkHtml>.
         
   
    </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section ID="id_link_b6b1fea0-2d20-8421-e053-2a95a90a097d">
               <id root="a0c6a512-564b-4838-96bd-8f128e0c0cab"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Tablet Carton</title>
               <text>
                  <paragraph>NDC 61958- 
  <content styleCode="bold">0801</content>-3
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Letairis 
   <sup>Â®</sup>
                        <br/>
                        <br/>
(ambrisentan) Tablets, 5 mg 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">R 
   <sub>x</sub> only 
  </content>
                  </paragraph>
                  <paragraph>Each tablet contains 5 mg of ambrisentan.</paragraph>
                  <paragraph>
                     <content styleCode="bold">10 tablets</content>
                  </paragraph>
                  <paragraph>Note to Authorized Dispenser: Provide a copy of the Letairis Medication
  <br/>
                     <br/>
Guide included in this carton to each patient.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">GILEAD</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_b6b1ed40-328d-762e-e053-2995a90a4d42"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="img_b6b1ed40-328d-762e-e053-2995a90a4d42">
                     <text>letairis-11.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="letairis-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_b6b1fea0-2d22-8421-e053-2a95a90a097d">
               <id root="313b7db6-8d1c-4a2f-b018-c8e6708afbdb"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mg Tablet Carton</title>
               <text>
                  <paragraph>NDC 61958- 
  <content styleCode="bold">0802</content>-3
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Letairis 
   <sup>Â®</sup>
                        <br/>
                        <br/>
(ambrisentan) Tablets, 10 mg 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">R 
   <sub>x</sub> only 
  </content>
                  </paragraph>
                  <paragraph>Each tablet contains 10 mg of ambrisentan.</paragraph>
                  <paragraph>
                     <content styleCode="bold">10 tablets</content>
                  </paragraph>
                  <paragraph>Note to Authorized Dispenser: Provide a copy of the Letairis Medication
  <br/>
                     <br/>
Guide included in this carton to each patient.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">GILEAD</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_b6b1ed40-328e-762e-e053-2995a90a4d42"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="img_b6b1ed40-328e-762e-e053-2995a90a4d42">
                     <text>letairis-12.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="letairis-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>